{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:22:42Z","timestamp":1761528162109,"version":"build-2065373602"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Northwell Health System"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.vph.2020.106764","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T20:41:54Z","timestamp":1593808914000},"page":"106764","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Angiotensin converting enzyme inhibitors and angiotensin receptor blockers have no effect on the outcomes of endovascular revascularization in tibial arterial occlusive disease"],"prefix":"10.1016","volume":"131","author":[{"given":"Amandeep","family":"Juneja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saqib","family":"Zia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aravinda","family":"Abeysekara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Shams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuldeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Schor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Deitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vph.2020.106764_bb0005","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/1358863X9700200310","article-title":"The epidemiology of peripheral arterial disease: importance of identifying the population at risk","volume":"2","author":"Criqui","year":"1997","journal-title":"Vasc. Med. Lond. Engl."},{"issue":"6","key":"10.1016\/j.vph.2020.106764_bb0010","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.vph.2020.106764_bb0015","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1177\/106002809302700617","article-title":"Effect of angiotensin-converting enzyme inhibitors on ventricular remodeling and survival following myocardial infarction","volume":"27","author":"Beckwith","year":"1993","journal-title":"Ann. Pharmacother."},{"issue":"3","key":"10.1016\/j.vph.2020.106764_bb0020","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Heart Outcomes Prevention Evaluation Study Investigators","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.vph.2020.106764_bb0025","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1161\/01.CIR.90.1.449","article-title":"Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation","volume":"90","author":"Rakugi","year":"1994","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.vph.2020.106764_bb0030","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0002-9149(02)02242-7","article-title":"Evidence that angiotensin-converting enzyme inhibitor use diminishes the need for coronary revascularization after stenting","volume":"89","author":"Ellis","year":"2002","journal-title":"Am. J. Cardiol."},{"issue":"12","key":"10.1016\/j.vph.2020.106764_bb0035","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"135","author":"Gerhard-Herman","year":"2017","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.vph.2020.106764_bb0040","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/1358863X15574321","article-title":"Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia","volume":"20","author":"Armstrong","year":"2015","journal-title":"Vasc Med Lond Engl."},{"key":"10.1016\/j.vph.2020.106764_bb0045","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/jama.2012.216237","article-title":"Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial","volume":"309","author":"Kurklinsky","year":"2013","journal-title":"J. Am. Med. Assoc."},{"issue":"5","key":"10.1016\/j.vph.2020.106764_bb0050","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/jama.2012.216237","article-title":"Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial","volume":"309","author":"Ahimastos","year":"2013","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.vph.2020.106764_bb0055","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/BF00168438","article-title":"Effects of angiotensin I and angiotensin II in blood vessels: greater influence of converting enzyme activity in the rabbit basilar artery","volume":"354","author":"Zerrouk","year":"1996","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"issue":"2","key":"10.1016\/j.vph.2020.106764_bb0060","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1291\/hypres.27.129","article-title":"Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress","volume":"27","author":"Yagi","year":"2004","journal-title":"Hypertens Res. Off. J. Jpn. Soc. Hypertens"},{"issue":"5","key":"10.1016\/j.vph.2020.106764_bb0065","first-page":"1390","article-title":"Angiotensin converting enzyme inhibitors maintain polytetrafluroethylene graft patency","volume":"22","author":"Sajgure","year":"2007","journal-title":"Nephrol. Dial. Transplant Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc."},{"issue":"6","key":"10.1016\/j.vph.2020.106764_bb0070","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/00000658-199112000-00014","article-title":"Chronic ACE inhibition reduces intimal hyperplasia in experimental vein grafts","volume":"214","author":"O\u2019Donohoe","year":"1991","journal-title":"Ann. Surg."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189120300914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189120300914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:19:08Z","timestamp":1761527948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189120300914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":14,"alternative-id":["S1537189120300914"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2020.106764","relation":{},"ISSN":["1537-1891"],"issn-type":[{"type":"print","value":"1537-1891"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiotensin converting enzyme inhibitors and angiotensin receptor blockers have no effect on the outcomes of endovascular revascularization in tibial arterial occlusive disease","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2020.106764","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106764"}}